Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy

Benesh, Gabrielle; Andriano, Tyler M.; Cohen, Steven R.

doi:10.1016/j.jdcr.2021.08.005

Cited by 5 publications

(1 citation statement)

References 6 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, many side effects occurred, associated specifically to long-term steroids use and rituximab infusions. In that context, we decided to explore the off-label use of ocrelizumab with the multiple sclerosis (MS) regimen, successfully used and reported by Benesh et al 3 In March 2022, the patient received the first ocrelizumab cycle, two doses of 300 mg intravenous (IV) ocrelizumab 2 weeks separated, together with IV premedication consisting of acetaminophen 1 g, methyprednisolone 100 mg and dexchlorpheniramine 5 mg. Clinical improvement was noted after 2 months without developing new skin lesions. After 6 months, his skin was completely healed (Figure 1), remaining only a small area of oral mucosa affected.…”

mentioning

confidence: 99%

Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management

de-la-Rosa-Fernández

Loizate-Sarrionandia

González-Rodríguez

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

Dear Editor, Pemphigus vulgaris (PV) is an autoimmune blistering disease caused by autoantibodies against keratinocyte desmosomal proteins, leading to intraepidermal blister formation. Rituximab, a chimeric anti-CD20 monoclonal antibody (mAb), is a first line therapy for moderate and severe forms of PV and pemphigus foliaceus. 1 However, sometimes this drug is not effective or not well tolerated and therapeutic alternatives are needed. Previous reports have been published exhibiting the value of other anti-CD20 drugs in PV management. 2

show abstract

mentioning

confidence: 99%